Jan

2012

Excelimmune, Inc.: Series C $12M

Posted in I - Series C, Q - 4Q11, R - NORTH EAST, X - Antibody, X - Antiinfective, X - MRSA, X - Oncology, XX - MA

Excelimmune (Woburn, MA) a preclinical-stage biopharmaceutical company focused on a recombinant polyclonal antibody platform for the treatment of infectious disease, closed a $12M Series C financing. Participants were not identified.

Jan

2012

Provenance Biopharmaceuticals, Corp.: Series A $8M

Posted in I - Series A, Q - 4Q11, R - NORTH EAST, X - Antibody, X - Immunology, X - Oncology, XX - MA

Provenance Biopharmaceuticals (Waltham, MA) a clinical-stage biopharmaceutical company focused on monoclonal antibody therapy for non-Hodgkins lymphoma and other hematological cancers, closed a $8M Series A financing. Participants include Alopexx Enterprises.

Jan

2012

arGEN-X, BV: Series B $37M

Posted in I - Series B, Q - 4Q11, R - INTERNATIONAL, X - Antibody, X - Autoimmune, X - Inflammation, X - Oncology, X - Therapeutic Platform

arGEN-X (Netherlands) a preclinical-stage biopharmaceutical company focused on a monoclonal antibody platform for autoimmunity, inflammation and oncology, closed a $37M Series B financing. Participants include Orbimed, Seventure, Credit Agricole Private Equity, Forbion Capital Partners, Life Science Partners, BioGeneration Ventures, Erasmus MC Biomedical Fund, Thuja Capital Healthcare and VIB.

Jan

2012

Zymeworks, Inc.: Series D $8.1M

Posted in I - Series D, Q - 3Q11, R - INTERNATIONAL, X - Antibody, X - Inflammation, X - Oncology

Zymeworks (Canada) a preclinical-stage biopharma focused on protein-based therapeutics for oncology and inflammatory disease, closed a $8.1M Series D financing. Participants include CTI Life Sciences Fund and Advanced Biotechnologies Venture Fund.
Thanx for your patience as we catch-up.

Oct

2011

Theraclone Sciences, Inc.: Series B $10.6M

Posted in I - Series B, Q - 3Q11, R - NORTH WEST, X - Antibody, X - Antiinfective, X - Inflammation, XX - WA

Theraclone Sciences (Seattle, WA) a preclinical-stage biopharmaceutical company focused on monoclonal antibodies for infectious disease and inflammation, closed a $10.6M Series B, bringing the total round to $41M. Participants include Arch Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures and Zenyaku Kogyo.

Jul

2011

Excelimmune, Inc.: Series B $10.5M

Posted in I - Series B, Q - 2Q11, R - NORTH EAST, X - Antibody, X - Antiinfective, X - MRSA, XX - MA

Excelimmune (Woburn, MA) a preclinical-stage biopharmaceutical company focused on a recombinant polyclonal antibody platform for the treatment of infectious disease, closed a $10.5M Series B financing. Participants were not identified.

Jul

2011

F-Star, GmbH: Series B $21.7M

Posted in I - Series B, Q - 2Q11, R - INTERNATIONAL, X - Antibody, X - Therapeutic Platform

F-star Biotech (Austria) a development-stage based biopharma company focused upon an antibody design platform, with product and indication(s) to be identified, closed a $10.8M Series A financing, bringing the total round to $25.8M. Participants include SR One, MP Healthcare Venture Management, Merck Serono Ventures, Atlas Venture, Aescap Venture, Novo Ventures and TVM Capital.

Mar

2011

Arsanis, Inc.: Series A $10M

Posted in I - Series A, Q - 1Q11, R - INTERNATIONAL, X - Antibody, X - Antiinfective

Arsanis (Austria) a development stage biopharma focused on fully human monoclonal antibodies against severe infectious diseases, closed a $10M A financing. Participants include OrbiMed Advisors, Polaris Venture Partners and SV Life Sciences.

Feb

2011

Symphogen, AS: Series F $135.4M

Posted in I - Series F, Q - 1Q11, R - INTERNATIONAL, X - Antibody, X - Autoimmune, X - Oncology

Symphogen (Denmark) a clinical-stage developer of recombinant polyclonal antibodies for the treatment of cancer and infectious and autoimmune diseases, closed a $135.4M Series F financing. Participants include Essex Woodlands Health Ventures, Novo, and Pensionskassernes Administration.

Jan

2011

Covagen, AB: Series A $6.5M

Posted in I - Series A, Q - 4Q10, R - INTERNATIONAL, X - Antibody, X - Fynomer, X - Therapeutic Platform

Covagen (Switzerland) a development-stage biopharmaceutical company focused on a protein scaffold platform (Fynomer) for therapeutic use, closed a $6.5M Series A financing. Participants include Seroba Kernel Life Sciences, Edmond de Rothschild Investment Partners, MP Healthcare Venture Management, Novartis Venture Fund and Ventech.

Jan

2011

NovImmune, SA: Series B $20.8M

Posted in I - Series B, Q - 4Q10, R - INTERNATIONAL, X - Antibody, X - Immunology, X - Inflammation

NovImmune (Switzerland) a clinical-stage biopharmaceutical company focused on monoclonal antibodies for the treatment of inflammation and immune related disorders, closed a $20.8M Series B financing. Participants include BZ Bank Aktiengesellschaft.

Nov

2010

Delenex Therapeutics, AG: Series A $14M

Posted in I - Series A, Q - 4Q10, R - INTERNATIONAL, X - Antibody, X - CNS, X - Dermatology

Delenex Therapeutics (Switzerland) a clinical-stage biopharmacetucial company developing therapeutic antibody fragments targeting CNS and dermatological disease, closed a $14M Series A financing. Participants include SV Life Sciences, HBM BioCapital, BioMed Partners and VI Partners.

Oct

2010

Femta Pharmaceuticals, Inc.: Series A $2.2M

Posted in I - Series A, Q - 3Q10, R - WEST, X - Antibody, X - Autoimmune, X - Inflammation, XX - CA

Femta Pharmaceuticals (San Diego, CA) a preclinical-stage biopharmaceutical company focused on monoclonal antibodies for the treatment of inflammation and autoimmune disease, closed a $2.2M Series A financing. Participants include Latterell Venture Partners.

« Previous Entries

to top of page...